samedan logo
 
 
 
spacer
home > ebr > autumn 2019 > recombinant human albumin
PUBLICATIONS
European Biopharmaceutical Review

Recombinant Human Albumin




Stem cell and gene therapies are some of the most cuttingedge and sophisticated therapeutic developments. They offer attractive alternative approaches to widely used treatments in areas such as multiple sclerosis, metabolic diseases, cardiovascular disease, and liver disease. The field is burgeoning, but developers still face challenges, some of which can be addressed by using recombinant human albumin (rHA).

As a long-established ingredient of cell culture media, albumin is well recognised for its ability to facilitate growth of many cell types. With the industry expanding the use of high-quality, fully recombinant, cGMP excipients in cryopreservation and formulation of stem cell therapies, the manufacturing, formulation, and handling challenges associated with the development of cell therapies must be explored. The authors will also assess how the use of rHA in the culture, expansion/differentiation, cryopreservation, and formulation of stem cells compares with alternative approaches such as albumin(s) derived from human (human serum albumin [HSA]) or bovine (FBS) serums.

Overcoming Cell Therapy Challenges

Stem cell therapy, a type of regenerative medicine, promotes the repair response of diseased, dysfunctional, or injured tissue using stem cells or their derivatives. Cell therapy can face many challenges in regard to reproducibly optimising, controlling and scaling cell isolation, expansion, transformation, cryopreservation, and final formulation. From a processing angle, cell viability, growth rate, and reproducibility can all present serious issues for manufacturers. These can be affected by aggregation of the cells, shear stresses, and contact of the cells with surfaces. Additionally, the maintenance of cell identity and multipotency and the assurance of cell survival during transformation can also lead to setbacks during development. Regarding formulation, quality control of final products, storage and transportation, apoptosis, loss of identity, multipotency, and safety all present considerable challenges. The cost of goods to manufacture a cell therapy can also have an enormous impact on the long-term viability and sustainability of the therapy as a commercialised product.



Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Phil Morton is the Chief Technology Officer heading up Albumedix’s Technology Group. He has over 20 years’ experience in the biopharmaceutical industry within process and product development both in R&D and manufacturing environments. His experience ranges from developing and transferring purification processes to formulation development and characterisation of these processes and products. Phil holds a PhD in Biochemical Engineering from Birmingham University, UK, and followed this with post-doctoral studies at Cambridge University, UK.

Dr Daniel Shelly is Director of Business Development at Albumedix, responsible for business development and outlicensing of Albumedix’s core technologies and recombinant albumin products for manufacture, stabilisation, and formulation of small molecule, peptide, protein, viral, and cell therapeutics. Daniel spent 10 years in cell culture, vaccine and gene therapy, clinical development and manufacturing. He has authored several peer reviewed articles and book chapters and is an adjunct professor in the University of Cincinnati Clinical Master’s program teaching Biologics Discovery and Biotechnology Management, US. He has degrees from Lehigh University (BA), US, The College of William and Mary (MA), US, Florida State University (PhD), US, and the University of Cincinnati (MBA), US. He did his postdoc at the University of Cincinnati College of Medicine, winning the APS Physiological Genomics Fellowship and an NIH NRSA.
spacer
Dr Phil Morton
spacer
spacer
spacer
Dr Daniel Shelly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Top ten tasks to prepare for the UK Conformity Assessment

As the medical device industry gears up to implement a new set of requirements following Brexit, Maetrics has released a concise guide summarizing the known requirements so far and priority areas where manufacturers can give their immediate attention.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement